BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Novartis
Harvard Business School
Daiichi Sankyo
Colorcon
US Army
Healthtrust
Mallinckrodt
McKinsey

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,879,706

« Back to Dashboard

Which drugs does patent 5,879,706 protect, and when does it expire?

Patent 5,879,706 protects VALTREX and is included in one NDA.

Protection for VALTREX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty countries.
Summary for Patent: 5,879,706
Title: Valaciclovir tablets containing colloidal silicon dioxide
Abstract:A tablet comprising at least 50% w/w valaciclovir and 0.05 to 3% w/w colloidal silicon dioxide in which the valaciclovir is present within granules of the tablets and the silicon dioxide, a lubricant and a microcrystalline cellulose filler are present extragranularly has excellent hardness and friability properties while still maintaining lubrication of the tablet granules.
Inventor(s): Carter; Barry Howard (Kinston, NC), Tillman; Lloyd Gary (Carlsbad, CA)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/875,172
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 5,879,706

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline VALTREX valacyclovir hydrochloride TABLET;ORAL 020487-002 Jun 23, 1995 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline VALTREX valacyclovir hydrochloride TABLET;ORAL 020487-001 Jun 23, 1995 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,879,706

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9501127Jan 20, 1995
PCT Information
PCT FiledJanuary 19, 1996PCT Application Number:PCT/GB96/00111
PCT Publication Date:July 25, 1996PCT Publication Number: WO96/22082

International Patents Family Members for US Patent 5,879,706

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Greece 3033677 ➤ Subscribe
Hong Kong 1002851 ➤ Subscribe
China 1131026 ➤ Subscribe
China 1494898 ➤ Subscribe
China 1313081 ➤ Subscribe
Cyprus 2182 ➤ Subscribe
Czech Republic 9702292 ➤ Subscribe
Czech Republic 296514 ➤ Subscribe
Germany 69607146 ➤ Subscribe
Denmark 0806943 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Moodys
Chubb
Novartis
Cipla
Mallinckrodt
Citi
Dow
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot